- Biopharma dealmaking in 2026: The recovery gathers speed in Q2It’s always darkest before the biotech dawn, and at no time was that more true than last summer, as biotech was experiencing a crisis of confidence. We tracked an industry-wide downturn in expect…Endpoints · 5d ago↗ source
- House passes bill directing FDA to update animal testing rulesThe U.S. House of Representatives passed the FDA Modernization Act 3.0 this week, and lawmakers and animal welfare advocates are celebrating the bill as a step toward a new era in preclinical testi…Fierce Biotech · 5d ago↗ source
- Vertex was only bidder for Crinetics in year's second-highest M&A premiumTo gain control of Crinetics Pharmaceuticals, Vertex Pharmaceuticals was willing to pay the second-highest premium so far in biopharma's banner year for M&A. And the Boston drugmaker was biddin…